Glucocorticoids Induce Partial Remission of Focal Segmental Glomerulosclerosis but Not Interstitial Nephritis in COVID-19 Acute Kidney Injury in an APOL1 Low-Risk Genotype White Patient

Piotr J. Nowak; Joanna Forycka; Natalia Cegielska; Karolina Harendarz; Małgorzata Wągrowska-Danilewicz; Marian Danilewicz; Tomasz Płoszaj; Maciej Borowiec; Rafał Wlazeł; Michał Nowicki

doi:10.12659/AJCR.933462

02 November 2021 : Case report Poland

Glucocorticoids Induce Partial Remission of Focal Segmental Glomerulosclerosis but Not Interstitial Nephritis in COVID-19 Acute Kidney Injury in an APOL1 Low-Risk Genotype White Patient

Challenging differential diagnosis, Rare coexistence of disease or pathology

Piotr J. Nowak^1ABCDEF*, Joanna Forycka^2BCEF, Natalia Cegielska^2BCEF, Karolina Harendarz^2BCEF, Małgorzata Wągrowska-Danilewicz^3BCD, Marian Danilewicz^4BCD, Tomasz Płoszaj^5BCD, Maciej Borowiec^5CDG, Rafał Wlazeł^6BCD, Michał Nowicki^1DEG

DOI: 10.12659/AJCR.933462

Am J Case Rep 2021; 22:e933462

Authors information Article notes Copyright and License information

Background Case Report Discussion Conclusions References:

View HTML version

Figure 1. A decrease of serum creatinine and C-reactive protein during glucocorticoid treatment. Initial dexamethasone dose of 6 mg/day was followed by 16 mg/day for 6 days then it was gradually reduced to 8, 4 and 2 mg/day. 2 units of Covid-19 convalescent plasma was transfused on day 3. Methylprednisolone pulse was administered after obtaining first kidney biopsy results.

Back to the Article

Glucocorticoids Induce Partial Remission of Focal Segmental Glomerulosclerosis but Not Interstitial Nephritis in COVID-19 Acute Kidney Injury in an APOL1 Low-Risk Genotype White Patient

Your Privacy